ECRAID-Prime is seeking to select compounds for treatment of non-hospitalised COVID-19 patients. To qualify, compounds need to be promising, potentially scalable and deployable in primary care. Additionally, they should have proof-of-principle evidence and preferably dosage and initial safety data already available. We are working closely with the Joint Advisory Access Mechanism (JAAM) regarding priority for intervention selection.
For more information, get in touch with ECRAID-Prime Co-coordinator Alike van der Velden.